- Home
- RADX
as 04-17-2025 4:00pm EST
Stocks
Radiopharm Theranostics Ltd is an Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialization of health technologies.
| Founded: | 2021 | Country: | Australia |
| Employees: | N/A | City: | N/A |
| Market Cap: | 31.8M | IPO Year: | N/A |
| Target Price: | $15.00 | AVG Volume (30 days): | 39.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.02 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.50 - $50.82 | Next Earning Date: | 02-26-2025 |
| Revenue: | $204,609 | Revenue Growth: | -94.50% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest RADIOPHARM THERANOSTICS LIMITED SPON ADS EACH REP 300 ORD News
RADX Breaking Stock News: Dive into RADX Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
New RAD202 Data Confirms Positive Tumor Uptake and Favorable Biodistribution
Simply Wall St.
2 months ago
Positive Signs As Multiple Insiders Buy Radiopharm Theranostics Stock
GlobeNewswire
2 months ago
New Clinical Trial Data Highlights RAD 101 (18F-Pivalate) Successfully Detects Brain Metastases
GlobeNewswire
3 months ago
Lantheus Increases to 12.16% shareholding in Radiopharm with US$5m (A$8m) Placement
GlobeNewswire
4 months ago
Radiopharm Announces Strategic Co-Development Partnership with Lantheus for Australia
GlobeNewswire
4 months ago
RAD 202 Receives Approval to Start Phase 1 Therapeutic Trial
Compare RADX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RADX RADIOPHARM THERANOSTICS LIMITED SPON ADS EACH REP 300 ORD - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.